Agilent Technologies released its SureSelect Kinome Target Enrichment Kit, which allows researchers to focus sequencing studies on expressed kinases — potentially important biomarkers of disease and potential drug targets.
The assay targets genes for more than 500 known kinases, plus a number of cancer genes and untranslated regions, according to the company. The assay was developed by Rene Bernards of The Netherlands Cancer Institute at Antoni van Leeuwenhoek Hospital.